A global phase I study of WVE-210201 (dystrophin exon 51) for the treatment of Duchenne muscular dystrophy (DMD)
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs WVE 210201 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacokinetics
- 09 Nov 2017 According to a WaVe life Sciences media release, this study including an open-label extension study are designed to include an interim efficacy readout of dystrophin expression from muscle biopsies in 2H 2019.
- 06 Nov 2017 According to a WaVe life Sciences media release, data from this study is expected in Q3 2018.
- 06 Nov 2017 Status changed from planning to recruiting, according to a WaVe life Sciences media release.